Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 479-485

  Corrao, Giovanni ^a   Scotti, Lorenza ^a   Zambon, Antonella ^a   Baio, Gianluca ^a   Nicotra, Federica ^a   Conti, Valentino ^a,b   Capri, Stefano ^c   Tragni, Elena ^d   Merlino, Luca ^e   Catapano, Alberico L ^d,f   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Regional Centre for Pharmacovigilance   (Italy)

^c CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Operative Unit of Territorial Health Services   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

Author keywords

Adherence; Administrative database; Cohort study; Cost effectiveness; Ischemic heart disease; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; ITALY; LEGAL DATABASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; AGED; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DATA MINING; DRUG COSTS; EMPIRICAL RESEARCH; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960700864     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.014     Document Type: Article

References (45)

1. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease. a meta-analysis of randomized controlled trials. J Am Med Ass 1999, 282:2340-2346.
2. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. Br Med J 2009, 338:b2376.
3. Murphy M.J., Wei L., Watson A.D., MacDonald T.M. 'Real-life' reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol 2008, 65:587-592.
4. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003, 326:1423.
5. Kamal-Bahl S.J., Burke T., Watson D., Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007, 99:530-534.
6. Helin-Salmivaara A., Lavikainen P., Korhonen M.J., et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther 2008, 30:2228-2240.
7. Poluzzi E., Strahinja P., Lanzoni M., et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008, 64:425-432.
8. Vinker S., Shani M., Baevsky T., Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care 2008, 14:388-392.
9. Bouchard M.H., Dragomir A., Blais L., Bérard A., Pilon D., Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007, 63:698-708.
10. Perreault S., Dragomir A., Blais L., et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009, 65:1013-1024.
11. Perreault S., Dragomir A., Blais L., Bérard A., Lalonde L., White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008, 66:706-716.
12. Liberopoulos E.N., Florentin M., Mikhailidis D.P., Elisaf M.S. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008, 7:717-725.
13. Shalev V., Chodick G., Silber H., Kokia E., Jan J., Heymann A.D. Continuation of statin treatment and all-cause mortality. a population-based cohort study. Arch Intern Med 2009, 169:260-268.
14. Corrao G., Conti V., Merlino L., Catapano A.L., Mancia G. Adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice. Clin Ther 2010, 32:300-310.
15. Prosser L.A., Stinnett A.A., Goldman P.A., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000, 132:769-779.
16. Murray C.J., Lauer J.A., Hutubessy R.C., et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361:717-725.
17. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003, 327:1264.
18. Pignone M., Earnshaw S., Tice J.A., Pletcher M.J. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006, 144:326-336.
19. Mihaylova B., Briggs A., Armitage J., Parish S., Gray A., Collins R. Heart protection study collaborative lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20536 people. BMJ 2006, 333:1145.
20. Franco O.H., der Kinderen A.J., De Laet C., Peeters A., Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 2007, 23:71-79.
21. Ward S., Lloyd Jones M., Pandor A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007, 11:1-160.
22. Pletcher M.J., Lazar L., Bibbins-Domingo K., et al. Comparing impact and cost-eEffectiveness of primary prevention strategies for lipid-lowering. Ann Int Med 2009, 150:243-254.
23. Corrao G., Cesana G., Merlino L. Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008, 2:117-125.
24. Rasmussen J.N., Chong A., Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. J Am Med Ass 2007, 297:177-186.
25. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveilar D., Rajakangas A.M., Pajak A. for the WHO MONICA Project Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994, 90:583-612.
26. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
27. Marubini E., Valsecchi M.G. Analysing survival data from clinical trials and observational studies 1995, John Wiley & Sons, New York.
28. Robert C.P. Simulation of truncated normal variables. Stat Comp 1995, 5:121-125.
29. Detsky A.S., Laupacis A. Relevance for cost-effectiveness analysis to clinicians and policy makers. JAMA 2007, 298:221-224.
30. Wang H., Zhao H. A study on confidence intervals for incremental cost-effectiveness ratios. Biometrical J 2008, 50:505-514.
31. Steenland K., Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol 2004, 160:384-392.
32. Lett H.S., Blumenthal J.A., Babyak M.A., et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Pychosom Med 2004, 66:305-315.
33. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107.
34. Ferketich A.K., Schwartzbaum J.A., Frid D.J., Moeschberger M.L. Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000, 160:1261-1268.
35. Ye X., Gross C.R., Schommer J., Cline R., St Peter W.L. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007, 29:2748-2757.
36. Marko N.F., Weil R.J. The role of observational investigations in compatative effectiveness research. Value Health 2010, 13:989-997.
37. Walley T., Folino-Gallo P., Schwabe U., Van Ganse E., Stephens P. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur J Clin Pharmacol 2004, 60:503-511.
38. Gaist D., Rodríguez L.A., Huerta C., Hallas J., Sindrup S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569.
39. Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C.
40. Chapman R.H., Ferrufino C.P., Kowal S.L., Classi P., Roberts C.S. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract 2010, 64:169-181.
41. Corrao G., Zambon A., Nicotra F., et al. Persistence with oral and transdermal hormone replacement therapy and hospitalization for cardiovascular outcomes. Maturitas 2007, 57:315-324.
42. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15:565-574.
43. McHorney C.A., Victor Spain C., Alexander C.M., Simmons J. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 2009, 31:2584-2607.
44. Yeaw J., Benner J.S., Walt J.G., Sian S., Smith D.B. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009, 15:728-740.
45. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005, 59:564-573.